Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006340 · ClinicalTrials.gov registry record · Phase 1
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
A Phase 1 study of Lymphoma and Leukemia, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Study locations
NCT00006340: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by Boston Medical Center.
NCT00006340 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Boston Medical Center. The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006340, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6
- Study locations
Study Summary
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.
Conditions Studied
Interventions
- DRUG arginine butyrate
- DRUG ganciclovir
Study Locations (6)
Other
- Hopital Necker - Paris
- Medizinische Hochschule Hannover - Hanover
- Istituto Nazionale per lo Studio e la Cura dei Tumori - Milan
Indiana
- Methodist Cancer Center at Methodist Hospital - Indianapolis
Massachusetts
- Cancer Research Center at Boston Medical Center - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1994-12 |
| Est. Completion | 2000-07 |
| Phase | Phase 1 |
What the finished NCT00006340 record still lists
NCT00006340 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which arginine butyrate is the first listed.
NCT00006340 lists 6 locations in 4 states (Other, Indiana, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00006340 about?
NCT00006340 is a clinical study titled "Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus". RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Bar...
What is the current status of trial NCT00006340?
This trial is currently completed. It is a Phase 1 study. The study started on 1994-12. Estimated completion is 2000-07.
What conditions does trial NCT00006340 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Precancerous Condition, Small Intestine Cancer.
What interventions are being tested in trial NCT00006340?
The interventions under investigation include: arginine butyrate (DRUG), ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00006340?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006340 being conducted?
This trial has 6 study locations across Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia